"Heparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
| Descriptor ID |
D006493
|
| MeSH Number(s) |
D09.698.373.400
|
| Concept/Terms |
Heparin- Heparin
- Unfractionated Heparin
- Heparin, Unfractionated
- Heparinic Acid
|
Below are MeSH descriptors whose meaning is more general than "Heparin".
Below are MeSH descriptors whose meaning is more specific than "Heparin".
This graph shows the total number of publications written about "Heparin" by people in this website by year, and whether "Heparin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 1 | 4 |
| 1995 | 1 | 4 | 5 |
| 1996 | 1 | 0 | 1 |
| 1997 | 3 | 0 | 3 |
| 1998 | 2 | 2 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 4 | 6 |
| 2002 | 3 | 0 | 3 |
| 2003 | 2 | 2 | 4 |
| 2004 | 1 | 6 | 7 |
| 2005 | 3 | 2 | 5 |
| 2006 | 0 | 1 | 1 |
| 2007 | 4 | 1 | 5 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 2 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 2 | 5 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 3 | 4 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 0 | 3 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heparin" by people in Profiles.
-
Management of acute chest syndrome in patients with sickle cell disease: a systematic review of randomized clinical trials. Expert Rev Hematol. 2022 06; 15(6):547-558.
-
Heparin-Induced Thrombocytopenia in Patients With Mechanical Circulatory Support. J Cardiothorac Vasc Anesth. 2022 07; 36(7):1880-1882.
-
Pediatric Extracorporeal Membrane Oxygenation Anticoagulation Protocol Associated with a Decrease in Complications. ASAIO J. 2022 02 01; 68(2):275-280.
-
Incidence of Heparin-Induced Thrombocytopenia in Patients With Newly Implanted Mechanical Circulatory Support Devices. Ann Pharmacother. 2022 05; 56(5):565-571.
-
Toward Optimal Anticoagulation Monitoring During Cardiopulmonary Bypass: It Is Still A Tough "ACT". J Cardiothorac Vasc Anesth. 2020 11; 34(11):2928-2930.
-
Comparison of anticoagulation and antiplatelet therapy for treatment of blunt cerebrovascular injury in children <10 years of age: a multicenter retrospective cohort study. Childs Nerv Syst. 2021 01; 37(1):47-54.
-
The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial. Catheter Cardiovasc Interv. 2020 12; 96(7):E688-E694.
-
Low ACT After High-Dose Heparin: Is Hemodilution Best Option to Pass by Syclla and Charybdis? A A Pract. 2019 12 15; 13(12):479.
-
Heparin-Induced Thrombocytopenia and Cardiac Surgery: Can We Do It All With Cangrelor? A A Pract. 2019 11 01; 13(9):366.
-
Clinical Impact of Protamine Titration-Based Heparin Neutralization in Patients Undergoing Coronary Bypass Grafting Surgery. J Cardiothorac Vasc Anesth. 2019 Aug; 33(8):2153-2160.